



Small, but heading for the big time

Nanobiotix shares transferred from compartment C to compartment B of the regulated market of Euronext in Paris

Paris, France, January 26, 2015 – **NANOBIOTIX** (Euronext: **NANO** – ISIN: **FR0011341205**), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces the transfer of its shares from compartment C to compartment B of the regulated market of Euronext in Paris with effect as from January 28, 2015, thanks to its stock market capitalization increase performances during 2014.

Compartment B groups together listed companies with a stock market capitalization of between 150 million and 1 billion euros. For the record, the average market capitalization of Nanobiotix over the last 60 trading days in 2014 was 249 million euros.

This transfer has no impact on the inclusion of Nanobiotix shares to NYSE Euronext indexes.

Laurent Levy, CEO of Nanobiotix comments: *“Following our admission to the SRD label in December, we are proud to announce the transfer of our shares from compartment C to compartment B of the regulated market of Euronext in Paris. This transfer rewards the dynamism and stock market performance of Nanobiotix during 2014. This operation and the strong increase of Nanobiotix shares liquidity with more than 1 billion 300 million euros traded this year, should improve the visibility of Nanobiotix to the international financial and industrial communities.”*

Compartment transfers were officially announced to market members by means of a notice to the market from Euronext on January 26, with an effective date of January 28, 2015.

Next financial press release: revenue for the 4th quarter of 2014 by February 27, 2015

• • •

About NANOBIOTIX: www.nanobiotix.com/fr

Nanobiotix (Euronext: **NANO** / ISIN: **FR0011341205**) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers including Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, Head and Neck Cancer, Glioblastoma, Prostate Cancer, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: **FR0011341205**, Euronext ticker: **NANO**, Bloomberg: **NANO:FP**). Based in Paris, France, the company opened an affiliate in the Boston Area in September 2014.

Contact

Nanobiotix

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com



Media relations

France - **NewCap**
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr

Outside France - **Instinctif Partners**
Melanie Toyne Sewell / Ruth Ashton
+44 (0) 207 457 2020
nanobiotix@instinctif.com